Lisanti Capital Growth LLC Lowers Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Lisanti Capital Growth LLC reduced its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 77.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,860 shares of the medical technology company’s stock after selling 241,700 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Alphatec were worth $1,086,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BluePath Capital Management LLC purchased a new position in shares of Alphatec in the 3rd quarter worth about $29,000. RiverPark Advisors LLC acquired a new stake in Alphatec during the 3rd quarter worth approximately $53,000. Provence Wealth Management Group purchased a new position in Alphatec in the third quarter valued at approximately $56,000. Van ECK Associates Corp acquired a new position in Alphatec during the third quarter valued at approximately $113,000. Finally, Amalgamated Bank grew its stake in Alphatec by 7.3% during the fourth quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock worth $147,000 after buying an additional 660 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Insider Activity

In related news, General Counsel Tyson Eliot Marshall sold 11,825 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $157,272.50. Following the sale, the general counsel now directly owns 305,095 shares in the company, valued at approximately $4,057,763.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, General Counsel Tyson Eliot Marshall sold 11,825 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $13.30, for a total value of $157,272.50. Following the completion of the sale, the general counsel now directly owns 305,095 shares of the company’s stock, valued at approximately $4,057,763.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO John Todd Koning sold 121,601 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $13.30, for a total transaction of $1,617,293.30. Following the transaction, the chief financial officer now owns 430,856 shares in the company, valued at approximately $5,730,384.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 285,069 shares of company stock valued at $3,971,495. Insiders own 29.12% of the company’s stock.

Analyst Ratings Changes

ATEC has been the topic of several recent research reports. Needham & Company LLC lifted their target price on shares of Alphatec from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, March 28th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Alphatec in a research report on Wednesday, March 20th. Wells Fargo & Company assumed coverage on Alphatec in a research report on Friday, February 9th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.63.

Alphatec Stock Performance

Shares of NASDAQ:ATEC traded up $0.30 during trading on Tuesday, hitting $13.58. 1,613,780 shares of the company traded hands, compared to its average volume of 1,586,872. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -8.76 and a beta of 1.48. Alphatec Holdings, Inc. has a one year low of $8.66 and a one year high of $19.14. The company has a quick ratio of 1.99, a current ratio of 2.86 and a debt-to-equity ratio of 6.54. The business’s fifty day moving average is $13.36 and its 200-day moving average is $13.55.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $131.90 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. Alphatec’s revenue for the quarter was up 30.3% compared to the same quarter last year. As a group, equities analysts predict that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.